CHROMOGRANIN-A IN THE DIAGNOSIS OF PROSTATE CANCER

The principal marker of neuroendocrine differentiation (NED) is chromogranin A (HGA). The purpose of this work is to determine the role of NED in diseases of the prostate gland by the level of HGA.

Materials and methods. The study included 304 men with various diseases of the prostate: BPH - 20; chronic prostatitis (CP) - 22; BPH and prostatic low-grade intraepithelial neoplasia (BPH+LDPIN) - 50; BPH and high degree PIN (BPH+HGPIN) - 32; localized prostate cancer (LPC) - 80; locally advanced PCA (LAPC) - 21; CRPC - 51. The last group United in patients LPC, LAPC and metastatic prostate cancer. All these groups of patients were performed blood sampling fasting with further definition of the level of HGA in serum by enzyme immunoassay. The reference values of HGA for this method are ranged from 0 to 3 nmol/L.

Results. During the analyzing of the results of the study they revealed a general trend of increasing of mean values of HGA of serum with the growth stage of prostate cancer, with a maximum of patients with CRPC. According to the analysis they revealed no significant correlation between age and HGA (r = 0,05) among all study groups. They noted the persistent correlation (r = 0,32; p <0,001) between HGA and PSA levels among all studied groups of patients. They traced some relationship between the amount of points Gleason and HGA (r = 0,19; p <0,05) in cases of LPC, LAPC and CRPC. Defining the relationship between HGA and stage of prostate cancer (LPC, LAPC and CRPC), we also found a correlation (r = 0,31, p <0,005) among these groups of patients.

Conclusions. HGA is a high interest for the early detection CRPC. Also with the help of HGA it seem to be quite promising to discover the most aggressive forms of prostate cancer. Definition of NED-tumor may be necessary for the analysis of a comprehensive approach to prostate cancer treatment selection.

1. Abrahamsson P.A. Neuroendocrine cells in tumour growth of the prostate // Endocr Relat Cancer. 1999a. Vol. 6. P. 503-519.

2. Abrahamsson P. A. Neuroendocrine differentiation in prostatic carcinoma // Prostate. 1999b. Vol. 39. P. 135-148.

3. Alessandro S., Vincenzo G., Maria A.G., et al. Chromogranin A and biochemical progressionfree survival in prostate adenocarcinomas submitted to radical prostatectomy. // Endocr Relat Cancer. 2007. Sep. Vol. 14. №. 3. P. 625 - 632.

4. Angelsen A., Syversen U., Haugen O.A., et al. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? // Prostate. 1997. Vol. 30. №. 1. P. 1-6.

5. Angelsen A., Syversen U., Stridsberg M., et al. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. // Prostate. 1997. Vol. 31. №. 2. P. 110 - 117.

6. Appetecchia M., Mecule A., Pasimeni G., et al. Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma // J Exp Clin Cancer Res. 2010. Vol. 29. P. 166.

7. Battaglia S., Casali A.M., Botticelli A.R. Age-related distribution of endocrine cells in the human prostate: a quantitative study // Virchows Arch. 1994. Vol. 424. №. 2. P. 165-168.

8. Bocan E.V., Mederle O., Sarb S., et al. Correlation between histopathological form and the degree of neuroendocrine differentiations in prostate cancer. // Rom J Morphol Embryol. 2011. Vol. 52. №. 4. P. 1215 – 1218.

9. Bonkhoff H., Stein U., Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers // Hum Pathol. 1994 Jan. Vol. 25. №. 1. P. 42-46.

10. Cabrespine A., Guy L., Gachon F., et al. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. // J Urol. 2006. Vol. 175. №. 4. P. 1347 - 1352.

11. Cabrespine A., Guy L., Gachon F., et al. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. // J Urol. 2006. Vol. 175. №. 4. P. 1347 - 1352.

12. Chuang C.K., Wu T.L., Tsao K.C. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. // J Formos Med Assoc. 2003. Vol. 102, №. 7. P. 480 - 485.

13. Denis L., Griffiths K., Khoury S., et al. Benign Prostatic Hyperplasia (BPH) // Paris. 1997. P. 95-96.

14. Di Sant'Agnese P. Neuroendocrine differentiation in prostatic carcinoma // Recent findings and new concepts. Cancer 1995. Vol. 75. P. 1850-1959.

15. Eriksson B., Arnberg H., Oberg K., et al. Chromogranins--new sensitive markers for neuroendocrine tumors // Acta Oncol. 1989. Vol. 28. №. 3. P. 325-329.

16. Ferrero-Pous M., Hersant A.M., Pecking A. Serum chromogranin - A in advanced prostate cancer. // BJU Int.. 2001. Vol. 88. №. 7. P. 790 – 796.

17. Cussenot O., Villette J.M., Valeri A., et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma // J Urol. 1996. Vol. 155. №. 4. P. 1340 - 1343.

18. Glinicki P., Jeske W. Chromogranin A (CgA) – the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood // Endokrynol. Pol. 2010. Vol. 61. P. 384-387.

19. Hansson J., Abrahamsson P.A. Neuroendocrine pathogenesis in adenocarcinoma of the prostate // Ann Oncol. 2001. Vol. 12. Suppl 2. P. 145-152.

20. Ischia R., Hobisch A., Bauer R., et al. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of prostate. // J Urol. 2000. Vol. 163. № 4. P. 1164 - 1165.

21. Kadmon D., Thompson T.C., Lynch G.R., Scardino P.T. Elevated plasma chromogranin - A concentrations in prostatic carcinoma. // J Urol. 1991. Vol. 146. № 2. P. 358 - 361.

22. Kotz S, Campbell B. Read, Balakrishnan N., Vidakovic B. (Eds.). Encyclopedia of statistical sciences. 16-volume set. 2nd Edition 2006. Vol.3. P. 1630-1631.

23. Peracchi M., Conte D., Gebbia C., et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1 // Eur J Endocrinol. 2003. Vol. 148. №. 1. P. 39-43.

24. Pretl K. Zur frage der endocrine menschlichen versteherdruse // Virchows Arch. 1944. Vol. 312. P. 392-404.

25. Quek M.L., Daneshmand S., Rodrigo S., et al. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. // Urology. 2006. Vol. 67. №. 6. Р. 1247 - 1252.

26. Sciarra A., Innocenzi M., Ravaziol M., et al. Role of neuroendocrine cells in prostate cancer progression // Urologia. 2011. Vol. 78. №. 2. P. 126-131.

27. Sciarra A., Voria G., Monti S., et al. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum Chromogranin A // Prostate. 2004. Vol. 58. №. 4. P. 421 - 428.

28. Hirano D., Minei S., Sugimoto S., et al. Implications of circulating chromogranin A in prostate cancer. Hirano D., Minei S., // Scand J Urol Nephrol. 2007. Vol. 41. №. 4. P. 297 - 301.

29. Tarjan M. Prognostic significance of focal neuroendocrine differentiation in prostate cancer: Cases with autopsy-verified cause of death // Indian J Urol. 2010. Vol. 26. №. 1. P. 41 - 45.

30. Wu J.T, Astill M.E., Liu G.H., Stephenson R.A. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. // J Clin Lab Anal. 1998. Vol. 12. №. 1. P. 20 - 25.